Monitoring real-time PrEP adherence
Partners Mobile Adherence to PrEP (PMAP)
Pre-exposure prophylaxis (PrEP) is a pill that can prevent HIV if taken daily. Dr. Jessica Haberer and colleagues set out to understand how frequently people in Thika, Kenya and Kampala, Uganda were taking PrEP in their daily lives.
A sub-study within the Partners Demonstration Project (n=1,013), PMAP enrolled 393 HIV-negative partners to receive daily surveys through mSurvey asking about their PrEP adherence and sexual behavior to help quantify their true HIV risk.
The study was funded by the U.S. National Institutes of Health, Bill & Melinda Gates Foundation, and the U.S. Agency for International Development.
See Dr. Haberer's presentation here.